Levo-Methasan

Levomethadone Hydrochloride, the active ingredient in Levo-Methasan, is a synthetic opioid presented as an oral tablet for oral use. It is employed in the management of opioid dependence and in the treatment of severe chronic pain, providing analgesic effects and reducing withdrawal symptoms in adult patients. The molecule acts as a full agonist at the µ‑opioid receptor, delivering consistent plasma concentrations that support both pain control and opioid substitution therapy.

GNH USA supplies Levo-Methasan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone Hydrochloride is used in opioid‑related pathways to treat dependence and pain.

- Opioid dependence: helps suppress withdrawal symptoms and supports maintenance therapy. - Severe chronic pain: provides potent analgesia when other opioids are insufficient. - Opioid substitution therapy: serves as an alternative to methadone for patients requiring a more predictable pharmacokinetic profile.

Levomethadone Hydrochloride may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac rhythm disturbance. - Seizures: rare convulsive episodes. - Severe hypotension: marked drop in blood pressure.

When prescribing Levomethadone Hydrochloride, clinicians should observe several safety measures to minimize risk.

- Assess dependence history: evaluate prior opioid use and withdrawal risk. - Monitor respiratory function: especially during initiation and dose changes. - Evaluate cardiac status: baseline ECG recommended due to QT prolongation potential. - Avoid use in severe hepatic impairment: dose adjustment may be required. - Counsel on constipation management: implement laxative regimen as needed. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Levomethadone Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - Co‑administration with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Drugs that prolong QT interval (e.g., certain antiarrhythmics, fluoroquinolones): increase risk of cardiac arrhythmia. - Alcohol: additive sedative effects.